Andrographis Paniculata Explained Simply
This page explains in simple terms what has been investigated about Andrographis paniculata and its main active compound andrographolide. It is written for interested laypeople without medical training.
1. What It Is About
Andrographis paniculata is a plant. In research, it is referred to by its botanical name, Andrographis paniculata (Burm. f.) Nees. It is studied in three forms: as the whole plant, as an extract (a concentrated preparation of the plant’s active compounds), and via its main active ingredient, andrographolide. An extract is a preparation in which the plant’s active compounds are enriched. Andrographolide is a single compound from the plant, often tested on its own. Modified forms of this compound, known as andrographolide derivatives, are also studied. In traditional Chinese medicine, the plant was used for colds, fever, sore throat, burning tongue, and snakebites 5. A key point for understanding all studies is this: the three forms are not the same. Findings from a single compound in cell culture do not automatically apply to a plant extract. Most research to date has been conducted in the laboratory; human studies have primarily focused on safety and COVID-19.
2. What Studies Show
In humans, there are only a few controlled studies, most of which relate to COVID-19. The most informative is a double-blind, randomised trial 3: 165 people with asymptomatic or mild COVID-19 received either an extract of Andrographis paniculata or a placebo for five days. “Randomised” means participants were assigned by chance, and “double-blind” means neither participants nor researchers knew who received what. By the final day, symptoms had improved in both groups, with no clear difference between them. Two specific symptoms improved more with the extract than with the placebo: headache on day one and loss of smell on day two. Overall, 80.7 % of those treated had fully recovered after five days. The most common side effect was mild diarrhoea; no damage to the liver or kidneys was observed. Plausible: A review cites randomised studies in which the plant, alone or in combination, reduced the severity of upper respiratory symptoms more than a placebo, particularly when treatment began early 1. A safety-focused review with meta-analysis examined 262 studies. Among 9,490 users of injections containing modified andrographolide forms, 383 (4.04 %) reported adverse effects 2. In a small capsule study using an aqueous extract, viral load measured in the blood decreased after five days; this is a laboratory finding and does not prove clinical benefit 4. Animal findings relate to lung cancer in mice 6 and joint wear in rats 7; such results are considered preclinical and not evidence in humans.
3. What Remains Unclear
Controlled human studies are small and short. They typically last five days and often include only a few hundred participants, with many designed as preliminary studies, sometimes alongside existing treatments. Preparations vary between studies, so results are not necessarily transferable. A second point is oral absorption: andrographolide is poorly absorbed, and the extent depends on the preparation. No studies examined the gut microbiome; a trial linking plant administration to measurable changes in gut flora has yet to be conducted. There are also no clinical human studies on immunological measurements, cancer, or joint diseases. The mechanism of action is primarily supported by cell culture and animal studies.
4. What This Means in Practice
When encountering a claim about Andrographis paniculata, first ask: what was studied? A standardised preparation, a simple extract, or a single modified compound? These are three different things, and safety data for one cannot be applied to another. Next, consider the type of study. The most frequently cited works on this plant are reviews and cell experiments, not human trials. High citation counts therefore do not reflect clinical evidence. Third, consider duration: existing human studies last only a few days. What needs to be clarified next is whether longer-term use remains safe, whether findings from cell and animal studies are confirmed in humans, and which preparation was tested for which indication.
All details with study numbers and sources: detailed page on Andrographis paniculata. For children: Andrographis paniculata for children.
Frequently Asked Questions
Is Andrographis paniculata a medicine?
In research, the plant, an extract from it and the single compound andrographolide are examined separately. Some medicines based on modified forms of andrographolide are administered by injection, whereas herbal preparations are different. Which of these are approved for which uses is not covered in the available material.
What does it mean when a result comes from a cell culture or an animal study?
Such experiments show what happens in a model, for example in cells in a dish or in mice and rats. They are considered preclinical, meaning preliminary work. Whether the same effect occurs in humans is not clarified by these results.
Why do many quotes say little about the effect in humans?
The most frequently cited works on this plant are reviews and cell experiments. They are often read and cited, but comparatively little has been tested in humans. The popularity in the scientific community and the relevance for human application are therefore not the same.
Sources
- 1Intharuksa A, Arunotayanun W, Yooin W, Sirisa-Ard P · 2022
- 2Shang YX, Shen C, Stub T, Zhu SJ, Qiao SY, Li YQ et al. · 2022
- 3Kanokkangsadal P, Mingmalairak C, Mukkasombat N, Kuropakornpong P, Worawattananutai P, Khawcharoenporn T et al. · 2023
- 4Songvut P, Payoong P, Okada PA, Rittapai N, Suntararuks S, Akanimanee J et al. · 2026
- 5Zeng B, Wei A, Zhou Q, Yuan M, Lei K, Liu Y et al. · 2022
- 6Wang XR, Jiang ZB, Xu C, Meng WY, Liu P, Zhang YZ et al. · 2022
- 7Yang K, Xie Q, Liang J, Shen Y, Li Z, Zhao N et al. · 2023
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.